The U.S. Food and Drug Administration (FDA) has approved SculpSure (Cynosure) for noninvasive lipolysis of the abdomen. It was previously FDA approved only for lipolysis of the flanks.
The hands-free SculpSure device uses a 1060nm laser and flexible applicator system to disrupt subcutaneous fat cells in approximately 25 minutes—with no downtime or surgery.
“SculpSure is the world’s first hyperthermic laser treatment for the noninvasive reduction of fat from the abdomen,” said plastic surgeon Lawrence S. Bass, MD, of Bass Plastic Surgery PLLC, who participated in the clinical trials. “Subjects in our study saw a statistically significant reduction in adipose layer thickness, with more than 90% reporting they were satisfied with the treatment.”
The technology is anticipated to launch later in 2015.
Photo copyright Getty Images.
